title: Is there a role for pulmonary metastasectomy with a curative intent in patients with metastatic urinary transitional cell carcinoma?
abstract: BACKGROUND
  Systemic chemotherapy remains the standard treatment for metastatic transitional cell carcinoma (TCC) of the urinary tract. For pulmonary metastases of several malignancies, surgical therapy for selected patients has become a treatment of choice to achieve cure. However, data on pulmonary metastasectomy for urinary TCC remain limited.
  
  
  METHODS
  From 1990 to 2005, 2,288 patients who underwent pulmonary metastasectomy for all types of malignancy were registered in the Metastatic Lung Tumor Study Group of Japan. Of these, we extracted 32 patients with TCC who underwent pulmonary metastasectomy with a curative intent from the database. We investigated the surgical outcomes of the patients, focusing on long-term progression-free survival (PFS) and modified PFS as a parameter for achieving a cure. In modified PFS, when the disease-free status had continued for longer than two years after repeated resection at the last follow-up, the first recurrence was not considered as an event.
  
  
  RESULTS
  The five-year overall survival and PFS rates were 50% and 26%, respectively. Including 3 patients who underwent a second pulmonary metastasectomy for recurrence, 9 patients survived without recurrence for more than 5 years, resulting in a modified five-year PFS rate of 40%. Multivariate analysis revealed that a pulmonary metastasis greater than 3 cm was a significantly poor prognostic factor. The modified five-year PFS rate for patients with a pulmonary metastasis smaller than 3 cm in diameter was 65%.
  
  
  CONCLUSIONS
  Pulmonary metastasectomy may have a curative role in the treatment of metastatic TCC in appropriately selected patients, especially those with a small solitary pulmonary metastasis.
authors.affiliation: Division of Thoracic Surgery, Tochigi Cancer Center, Utsunomiya, Tochigi, Japan. hmatsugu@tcc.pref.tochigi.lg.jp
authors.forename: Haruhisa
authors.initials: H
authors.lastname: Matsuguma
authors.forename: Ichiro
authors.initials: I
authors.lastname: Yoshino
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ito
authors.forename: Tomoyuki
authors.initials: T
authors.lastname: Goya
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Matsui
authors.forename: Jun
authors.initials: J
authors.lastname: Nakajima
authors.forename: Norihiko
authors.initials: N
authors.lastname: Ikeda
authors.forename: Sakae
authors.initials: S
authors.lastname: Okumura
authors.forename: Satoshi
authors.initials: S
authors.lastname: Shiono
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Nomori
mesh_terms: D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011013:Pneumonectomy / Q000401:mortality; D011379:Prognosis; D013908:Thoracotomy / Q000401:mortality; D047368:Tumor Burden; D014571:Urologic Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000473:pathology / Q000601:surgery*